| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 8, 2021 | NBIX Neurocrine Biosciences Inc | Abernethy Matt57 | Chief Financial Officer | Sell | 2,910 | $116.82 | $339,941.51 | -9.4% | - | - | |
| Feb 8, 2021 | EBS Emergent Biosolutions Inc. | Kramer Robert | President And CEO | Sell | 45,397 | $120.03 | $5,449,001.91 | -14.0% | - | - | |
| Feb 8, 2021 | LFCR Lifecore Biomedical, Inc. \de\ | Morberg John D | Chief Financial Officer | Buy | 2,000 | $10.97 | $21,940.00 | +100.0% | - | - | |
| Feb 8, 2021 | NBIX Neurocrine Biosciences Inc | Benevich Eric62 | Chief Commercial Officer | Sell | 5,079 | $116.38 | $591,088.69 | -6.4% | - | - | |
| Feb 8, 2021 | NBIX Neurocrine Biosciences Inc | Gorman Kevin Charles55 | Chief Executive Officer | Sell | 12,888 | $116.26 | $1,498,368.03 | -0.7% | - | - | |
| Feb 8, 2021 | NBIX Neurocrine Biosciences Inc | Gano Kyle54 | Chief Business Development Off | Sell | 6,370 | $115.65 | $736,702.16 | -1.2% | - | - | |
| Feb 8, 2021 | NBIX Neurocrine Biosciences Inc | Grigoriadis Dimitri E. | Chief Research Officer | Sell | 3,313 | $116.16 | $384,821.80 | -1.0% | - | - | |
| Feb 8, 2021 | NBIX Neurocrine Biosciences Inc | Cooke Julie59 | Chief Human Resources Officer | Sell | 1,943 | $115.84 | $225,075.71 | -4.8% | - | - | |
| Feb 8, 2021 | NBIX Neurocrine Biosciences Inc | Bozigian Haig P. | Chief Development Officer | Sell | 4,546 | $116.33 | $528,857.09 | -0.7% | - | - | |
| Feb 8, 2021 | NBIX Neurocrine Biosciences Inc | Lloyd-Smith Malcolm49 | Chief Regulatory Officer | Sell | 4,126 | $116.26 | $479,668.44 | -3.2% | - | - | |
| Feb 5, 2021 | LFCR Lifecore Biomedical, Inc. \de\ | Morberg John D | Chief Financial Officer | Buy | 2,000 | $10.87 | $21,740.00 | New | - | - | |
| Feb 5, 2021 | LNTH Lantheus Holdings, Inc. | Maeusli Heinz Christoph | Director | Buy | 1,000 | $17.94 | $17,940.00 | +8.9% | - | - | |
| Feb 4, 2021 | AMPH Amphastar Pharmaceuticals, Inc. | Zhang Jack Y.45 | CEO &Chief Scientific Officer | Sell | 41,869 | $18.69 | $782,342.84 | -0.3% | -4.8% | +32.8% | |
| Feb 3, 2021 | KNSA Kiniksa Pharmaceuticals International, Plc | Beetham Thomas W. | EVP &Chief Legal Officer | Sell | 2,477 | $22.09 | $54,716.93 | -0.8% | - | - | |
| Feb 3, 2021 | PCRX Pacira Biosciences, Inc. | Stack David M67 | CEO And Chairman | Sell | 42,500 | $70.31 | $2,988,133.00 | -9.2% | - | - | |
| Feb 2, 2021 | AMPH Amphastar Pharmaceuticals, Inc. | Zhang Jack Y.45 | CEO &Chief Scientific Officer | Sell | 37,931 | $18.43 | $698,940.89 | -0.3% | - | - | |
| Feb 1, 2021 | BTAI Bioxcel Therapeutics, Inc. | Steinhart Richard I87 | Chief Financial Officer | Sell | 3,750 | $48.15 | $180,562.50 | -71.4% | - | - | |
| Feb 1, 2021 | AMPH Amphastar Pharmaceuticals, Inc. | Petersen Floyd F.51 | Director | Sell | 639 | $18.26 | $11,668.91 | -0.9% | - | - | |
| Feb 1, 2021 | AMRN Amarin Corp Plc\uk | Ketchum Steven B | Chief Scientific Officer | Sell | 217,728 | $8.06 | $1,754,133.55 | -21.6% | - | - | |
| Feb 1, 2021 | DVAX Dynavax Technologies Corp | Janssen Robert71 | Senior Vice President | Sell | 42,155 | $10.64 | $448,529.20 | -32.8% | - | - | |
| Jan 29, 2021 | LNTH Lantheus Holdings, Inc. | Maeusli Heinz Christoph | Director | Buy | 1,000 | $16.13 | $16,130.00 | +9.8% | - | - | |
| Jan 27, 2021 | AMRN Amarin Corp Plc\uk | Ketchum Steven B | Chief Scientific Officer | Sell | 421,629 | $8.01 | $3,378,131.34 | -31.4% | - | - | |
| Jan 26, 2021 | LQDA Liquidia Corp | Eshelman Ventures, LLC | 10% Owner | Sell | 1,762,162 | $3.12 | $5,502,527.06 | -40.4% | - | - | |
| Jan 26, 2021 | NBIX Neurocrine Biosciences Inc | Benevich Eric62 | Chief Commercial Officer | Sell | 5,477 | $120.02 | $657,371.27 | -7.8% | - | - | |
| Jan 26, 2021 | NBIX Neurocrine Biosciences Inc | Lyons Gary A54 | Director | Sell | 2,000 | $120.02 | $240,046.56 | -0.4% | - | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.